On July 23, 2026, a new publication involving the humanin analog S14G-humanin (HNG) appeared in the European Journal of Pharmacology. The paper is titled "S14G-humanin (HNG) ameliorates diabetic nephropathy tubular injury by inhibiting Z-DNA/ZBP1-mediated necroptosis."
The publication is indexed under PubMed ID 42492881. Humanin remains classified as an unapproved research compound, and this publication is presented here strictly as a record of new research literature.
No specific findings, efficacy data, or safety conclusions from the study are detailed beyond the title itself. The title indicates the research focus on tubular injury in the context of diabetic nephropathy and a proposed mechanism involving Z-DNA and ZBP1-mediated necroptosis, but this brief does not interpret or expand on outcomes.
This entry documents the existence and placement of the publication in the scientific record. Readers interested in the broader context of humanin research can consult the compound overview for additional background.